Pharmaron Beijing (03759) released its performance for the first three quarters, with a net profit attributable to shareholders of 1.141 billion yuan, a decrease of 19.76% year-on-year.

Pharmaron Beijing (03759) released its performance report for the first three quarters of 2025. The group achieved operating income of 10.86 billion yuan, a year-on-year increase of 14.38%; net profit attributable to shareholders of the listed company was 1.41 billion yuan, a year-on-year decrease of 19.76%; basic earnings per share were 0.6477 yuan.